WARN notices filed with the state show more job cuts due in the health sector as companies look to cut costs and streamline ...

By leveraging AI, drug developers are moving beyond incremental gains in efficiency and engaging previously undruggable ...

Plus: Here’s how Epic founder and CEO Judy Faulkner will keep her medical records company private, independent and ...

Poseida Therapeutics' lead allogeneic chimeric antigen receptor T-cell candidate it is co-developing with Roche will advance to Phase Ib.

Focus is turning to the development of peptide analogues of antibody-derived radiotherapeutics, according to Dr Dave Madge.

Bristol Myers Squibb wins approval for the first novel schizophrenia drug in decades; Pfizer pulls Oxbryta from the market; ...

Avidity Biosciences, Inc. surges on positive developments in AOCs for muscular disorders, strategic partnerships, and ...

Health Care Select Sector SPDR Fund ETF (XLV) outperformed the S&P 500 in Q3 2024. Bristol-Myers led growth while Moderna ...

SK bioscience completed the acquisition of German CDMO company IDT Biologika with over a century of history that enables ...

Volastra Therapeutics, a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VLS-1488, the company's internally ...